Simultaneous Care in Recurrent and/or Metastatic Head and Neck Cancer: the SupCare Study

Simultaneous Care in Recurrent and/or Metastatic Head and Neck Cancer: the SupCare Study

This is a late phase II, prospective, multicenter randomized study, to assess the value of early palliative care integrated with the standard oncologic care in patients with Recurrent Metastatic (RM) Head and Neck Cancer (HNC) proposed to first line palliative systemic treatment.

The study randomizes patients in a 1:1 fashion to standard oncologic care, in which the palliative care is requested as needed (reactive approach) or to early palliative care integrated with the standard oncologic care (proactive approach).

Standard of Care: the oncologist will be the main referral of the patient, deciding the therapeutic approach, the assessments requested, in terms of type of exams and timing and the need of possible further support from other expertise. The oncologist will base the choices also upon the results of the Liverpool Head and Neck Patient Concern Inventory (PCI-H&N) and the patient's preferences. At the end of the first oncological visit, the physician will be asked to predict the survival of the patient.

Integrated approach: Besides the Oncology visit, patient will have the palliative care expert visit and follow up. The oncologist will define the therapeutic approach and the assessments requested, in terms of type of exams and timing. The palliative care clinician and the oncologist will judge the burden of symptoms and together they will propose the suggested interventions to relief the symptoms, with a particular attention to a validated instrument (the PCI-H&N) and patient priority questionnaire's results.

Stratification Factors

• Institution
• Performance Status (PS) (0 vs 1-2)
• Presence of any caregiver at home
• Type of treatment (Immunotherapy alone vs any other combination)

Study duration: the total study duration is estimated at 36 months, with a total accrual time estimated to be 24 months from first patient in (FPI) and with an additional follow-up period of 12 months.

End of study occurs when all patients have completed their end of study visit and the study is mature for all analyses defined in the protocol and the database has been cleaned and frozen for these analyses.

Inclusion Criteria:

• Patients over 18 years of age
• Histological diagnosis of HNC of epithelial origin. Any sub-site of head and neck is eligible except endocrine tumours such as thyroid and parathyroid cancer
• First diagnosis of recurrent disease and/or distant metastasis; with recurrent disease not amenable to salvage surgery or re-irradiation
• Patient candidate to any first line systemic treatment
• Life expectancy more than 3 months
• PS Eastern Cooperative Oncology Group (ECOG) ≤2
• Adequate cognitive and reading abilities.
• Availability of baseline scores for Emotional Functioning and Pain
• Patient agrees to complete questionnaires at week 6, 15, 24 and 52 after systemic treatment start
• Before patient 's enrolment, written informed consent must be given according to International Council for Harmonisation (ICH)/Good Clinical Practice (GCP), and national/local regulations.

Exclusion Criteria:

• Patients requiring a palliative care consultation right from the beginning of treatment
• Cutaneous primary cancer
• Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be assessed and discussed with the patient before the enrolment in the study